Thursday, April 4, 2013
Researchers at the Dana-Farber Cancer Institute have identified a glutamine metabolism pathway that is
activated by oncogenic K-Ras
in pancreatic cancers.1 Moreover, the team found three different
enzyme targets within the pathway that could be blocked to specifically inhibit
proliferation of the malignant cells.
Safety and specificity
Beyond the pancreas
Martz, L. SciBX 6(13); doi:10.1038/scibx.2013.302 Published online
April 4, 2013
J. et al. Nat. Med.; published online March 27, 2013;
doi:10.1038/nature12040 Contact: Lewis C. Cantley, Weill Cornell Medical
College, New York, N.Y. e-mail: firstname.lastname@example.org
Contact: Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, Mass. e-mail:
H. et al. Cell 149, 656-670 (2012)
COMPANIES AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Beth Israel Deaconess Medical Center, Boston, Mass.
Cancer Research Technology Ltd., London, U.K.
Cancer Research UK, London, U.K.
Cornerstone Pharmaceuticals Inc., Cranbury, N.J.
Dana-Farber Cancer Institute, Boston, Mass.
Harvard Medical School, Boston, Mass.
Massachusetts General Hospital, Boston, Mass.
The University of Texas MD Anderson Cancer Center, Houston, Texas
Weill Cornell Medical College, New York, N.Y.